Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma S.A., Pereira, Colombia; Grupo de Investigación Biomedicina, Fundación Universitaria Autónoma de las Américas, Pereira, Colombia.
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira, Audifarma S.A., Pereira, Colombia.
Drug Alcohol Depend. 2020 May 1;210:107962. doi: 10.1016/j.drugalcdep.2020.107962. Epub 2020 Mar 19.
Benzodiazepines have low abuse potential, but patients often develop physical dependence and neurological impairments. The objective of this study was to investigate treatment cessation and use of high doses in long-term benzodiazepine users in Colombia.
Retrospective study. Patients who used benzodiazepines for at least six months (long-term) were selected from a prescription database and followed from initiation of benzodiazepine treatment for up to 30 months. We investigated treatment duration and compared patients who received normal and high (≥2 mean prescribed daily dose) doses.
Only 1255 (6.1 %) out of 20,567 patientsprescribed benzodiazepines became long-term users; their mean age was 60.6 years (SD=20.0) and 61.7 % were women. Mean high doses were used by 42.5 % (n=534) of the sample. Age under 20 years was a protector, whereas the long half-life benzodiazepines and use of other neurological medications were predictors of high dosage. Overall, 44.8 % (n=563) of the sample was still using benzodiazepines at the end of the study period. The use of antidepressants, antipsychotics, and anticonvulsants were negatively associated with cessation of benzodiazepine treatment.
A low proportion of patients starting benzodiazepines became long-term users. Nearly half of them used high doses and continued the medication for up to 30 months. Use of concomitant neurological drugs was associated with higher doses and less cessation.
苯二氮䓬类药物滥用潜力低,但患者常出现躯体依赖和神经损伤。本研究旨在调查哥伦比亚长期使用苯二氮䓬类药物患者的停药和高剂量使用情况。
回顾性研究。从处方数据库中选择至少使用苯二氮䓬类药物 6 个月(长期)的患者,并从开始使用苯二氮䓬类药物治疗开始随访最多 30 个月。我们调查了治疗持续时间,并比较了接受正常和高(≥2 平均规定日剂量)剂量的患者。
在 20567 名开具苯二氮䓬类药物的患者中,仅有 1255 名(6.1%)成为长期使用者;他们的平均年龄为 60.6 岁(标准差=20.0),61.7%为女性。样本中 42.5%(n=534)使用高剂量。20 岁以下年龄是保护因素,而半衰期较长的苯二氮䓬类药物和使用其他神经药物是高剂量的预测因素。总体而言,在研究结束时,样本中仍有 44.8%(n=563)在使用苯二氮䓬类药物。抗抑郁药、抗精神病药和抗惊厥药的使用与苯二氮䓬类药物治疗的停药呈负相关。
开始使用苯二氮䓬类药物的患者中,低比例成为长期使用者。其中近一半使用高剂量,并持续用药长达 30 个月。使用伴随的神经药物与更高的剂量和更少的停药有关。